Article

A two-stage clinical trial of Phyllanthus amarus in hepatitis B carriers: failure to eradicate the surface antigen.

Dr Balabhai Nanavati Hospital and Research Center, Juhu, Bombay.
Indian Journal of Gastroenterology 02/1994; 13(1):7-8.
Source: PubMed

ABSTRACT There have been conflicting data in literature about the value of Phyllanthus amarus in treating hepatitis B virus-related disorders.
To evaluate the role of Phyllanthus amarus in eradication of the virus in hepatitis B carriers.
Phyllanthus amarus was administered to 30 asymptomatic carriers of hepatitis B surface antigen (HBsAg) in a dosage of 250 to 500 mg thrice daily for 4 to 8 weeks.
None of the 30 subjects cleared HBsAg. Phyllanthus amarus was well tolerated, with no clinical side effects or changes in the organ profiles for safety evaluation.
Phyllanthus amarus is not effective in clearing HBsAg in asymptomatic carriers of the antigen.

1 Bookmark
 · 
225 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND AND AIMS: Nonalcoholic steatohepatitis (NASH) is a common liver disease that may progress to cirrhosis and hepatocellular carcinoma. There is currently no approved pharmacological treatment for NASH. Phyllanthus urinaria is a commonly used hepatoprotective herb that ameliorates NASH in animal studies. We aimed to test the hypothesis that Phyllanthus was superior to placebo in improving histological nonalcoholic fatty liver disease (NAFLD) activity score. METHODS: This was a placebo-controlled parallel-group double-blind randomized controlled trial. Patients with histology-proven NASH were randomized to receive Phyllanthus or placebo for 24 weeks. The primary endpoint was change in NAFLD activity score from baseline to week 24. Secondary endpoints included changes in individual histological parameters, liver biochemistry and metabolic profile. RESULTS: We enrolled 60 patients (40 received Phyllanthus and 20 received placebo). The change in NAFLD activity score was -0.8±1.4 in the Phyllanthus group and -0.3±1.3 in the placebo group (P=0.24). The change in steatosis, lobular inflammation, ballooning and fibrosis was also similar between the two groups. Within the Phyllanthus group, although there was reduction in hepatic steatosis (-0.2±0.7; P=0.039) and ballooning grades (-0.4±0.5; P<0.001), the change was small and of limited clinical significance. Furthermore, there was no significant difference in the changes in alanine aminotransferase, aspartate aminotransferase, fasting glucose and lipid profile between the two groups. CONCLUSIONS: Phyllanthus is not superior to placebo in improving NAFLD activity score in NASH patients.
    Journal of Gastroenterology and Hepatology 10/2012; · 3.33 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: AdEdApO, A. A., M. O. AbA t An, O. O. OlOrunsOgO: Effects of some plants of the spurge family on haematological and biochemical parameters in rats. Vet. arhiv 77, 29-38, 2007. AbstrAct The effects of five suspected poisonous plants of the spurge family ( euphorbiaceae ) i.e. alchornea cordifolia Schum and Thorn, Cnidoscolus acontifolius Mill, Phyllanthus amarus Schum and Thorn, Phyllanthus muelleriarus Exell and securinega virosa Baill, which are commonly found in Nigerian pasture were evaluated in albino rats using crude aqueous extracts for 14 days. All the extracts were administered orally. Changes in haematological and biochemical parameters were used as indices of toxicosis. The extracts of the plants caused a significant reduction (P
  • Source